PsyBio Therapeutics Corp. has submitted its first pre-Investigational New Drug (IND) application meeting request to the US Food and Drug Administration as part of the regulatory submission process.
The FDA's IND Consultation Program fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission.
PsyBio said it is dedicated to working towards obtaining all necessary regulatory approvals for its therapeutics under development and intends to submit its most promising potential therapeutic candidates to the appropriate regulatory body as part of the approval process.
READ: PsyBio Therapeutics inducted into AdvisorShares Psychedelics ETF
The company added that the submission of its pre-IND meeting request for collaborative discussions with the FDA was submitted in anticipation of filing the first of several clinical IND packages.
"This is a significant milestone for PsyBio as there are currently no approved indications for psilocybin or other similar compounds," said Dr. Michael Spigarelli, PsyBio's chief medical officer, in a statement.
"We look forward to working with the FDA to define what would be considered sufficient proof of safety and efficacy within the target populations. This is the first step to defining an acceptable medical use for these compounds, a critically necessary component in order to facilitate further developing and manufacturing at the necessary scale for this new class of potential therapeutics."
PsyBio CEO Evan Levine added: "This submission firmly establishes PsyBio among the top biotechnology companies actually seeking regulatory approval for their psychoactive therapeutic candidates. The company's logical and validated testing approach allows PsyBio to effectively design and develop therapeutics to potentially treat specific clinical conditions and submit those to the appropriate regulatory agencies for approval and marketing authorization. PsyBio is doing this as part of our commitment to research and develop potential therapeutics for mental and neurological health."
PsyBio is an intellectual property-driven biotechnology company developing novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham